Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial

IMPORTANCE: The combination of a triple-drug chemotherapy regimen with an anti–epidermal growth factor receptor (EGFR) agent as a first-line treatment of metastatic colorectal cancer (mCRC) showed promising activity along with safety concerns in single-arm phase 2 trials. The role of maintenance fol...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Cremolini, Chiara, Antoniotti, Carlotta, Lonardi, Sara, Aprile, Giuseppe, Bergamo, Francesca, Masi, Gianluca, Grande, Roberta, Tonini, Giuseppe, Mescoli, Claudia, Cardellino, Giovanni Gerardo, Coltelli, Luigi, Salvatore, Lisa, Corsi, Domenico Cristiano, Lupi, Cristiana, Gemma, Donatello, Ronzoni, Monica, Dell’Aquila, Emanuela, Marmorino, Federica, Di Fabio, Francesca, Mancini, Maria Laura, Marcucci, Lorenzo, Fontanini, Gabriella, Zagonel, Vittorina, Boni, Luca, Falcone, Alfredo
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885260/
https://ncbi.nlm.nih.gov/pubmed/29450468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5314
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados